e-learning
resources
Stockholm 2002
Monday 16.09.2002
COPD - general -3
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD
A. Ilic, B. Milenkovic, V. Petrovic (Belgrade, Yugoslavia)
Source:
Annual Congress 2002 - COPD - general -3
Session:
COPD - general -3
Session type:
Thematic Poster Session
Number:
1671
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Ilic, B. Milenkovic, V. Petrovic (Belgrade, Yugoslavia). The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD. Eur Respir J 2002; 20: Suppl. 38, 1671
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021
Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018
Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers.
Source: International Congress 2017 – New Mechanistic Findings in COPD
Year: 2017
Regional deposition of
99m
Tc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007
Intra-epithelial polymerization, accumulation and secretion of alpha
1
antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Epithelial cell biology
Year: 2010
Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD)
Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases
Year: 2011
Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017
Year: 2017
Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Similar pattern of interleukin-32 in AAT deficient and AAT replete patients with COPD
Source: Annual Congress 2009 - COPD: basic science and clinical studies
Year: 2009
A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study
Source: Eur Respir J 2005; 26: Suppl. 49, 361s
Year: 2005
Patterns of exacerbations in alpha 1 antitrypsin deficiency (AATD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008
Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Exercise in COPD
Year: 2010
GSTP1 polymorphisms in patients with COPD and alpha-1 antitrypsin deficiency
Source: Eur Respir J 2003; 22: Suppl. 45, 384s
Year: 2003
Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil
Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population
Year: 2013
Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 501s
Year: 2003
Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil
Source: Eur Respir J 2003; 22: Suppl. 45, 499s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept